{
  "id": "resp_08dd44399a824f1a00693c90014d0c81958ab6b61cddd4096f",
  "object": "response",
  "created_at": 1765576705,
  "status": "completed",
  "background": false,
  "billing": {
    "payer": "developer"
  },
  "error": null,
  "incomplete_details": null,
  "instructions": null,
  "max_output_tokens": null,
  "max_tool_calls": null,
  "model": "gpt-5.2-2025-12-11",
  "output": [
    {
      "id": "rs_08dd44399a824f1a00693c9001bac4819580f80a2f62ad3faa",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_08dd44399a824f1a00693c9003d76c8195b068053a69156b14",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "\"CDK12/13 inhibitor\" NCT"
      }
    },
    {
      "id": "rs_08dd44399a824f1a00693c900653ac81958bd18c5f70c66847",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_08dd44399a824f1a00693c900a0dac8195ad5d4c920bd612ca",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "NCT06600789 CT7439 CDK12/13"
      }
    },
    {
      "id": "rs_08dd44399a824f1a00693c900cb1e481959ecb7ade8bf7b935",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_08dd44399a824f1a00693c900d7f788195a1732513f9248fa7",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://clinicaltrials.gov/study/NCT06600789"
      }
    },
    {
      "id": "rs_08dd44399a824f1a00693c900e88d48195a8067332f5d4148f",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_08dd44399a824f1a00693c900fdfe481959e2ec57dbffc2264",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "site:clinicaltrials.gov \"NCT06600789\""
      }
    },
    {
      "id": "rs_08dd44399a824f1a00693c9012f1f081959a382290687db8f2",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_08dd44399a824f1a00693c90167f408195ac34cb4379c84609",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://cdek.pharmacy.purdue.edu/trial/NCT06600789/"
      }
    },
    {
      "id": "rs_08dd44399a824f1a00693c901822488195b14b3e382f372051",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_08dd44399a824f1a00693c901c5ff08195b7bd2fa90a708c15",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html"
      }
    },
    {
      "id": "rs_08dd44399a824f1a00693c901e2f508195bc99dc66a1243c27",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_08dd44399a824f1a00693c901fab908195ad8ea9ee437ac9d2",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "find_in_page",
        "pattern": "CT7439",
        "url": "https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-025-02101-x"
      }
    },
    {
      "id": "rs_08dd44399a824f1a00693c90215c3c8195ae466a776d8e1d6a",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_08dd44399a824f1a00693c902876608195ade1d5a207e87fd1",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://www.jci.org/articles/view/193745/sd/6"
      }
    },
    {
      "id": "rs_08dd44399a824f1a00693c902a469c81958eb63fc5990bfdb8",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_08dd44399a824f1a00693c902ad9688195a77a315916582203",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "find_in_page",
        "pattern": "NCT",
        "url": "https://www.jci.org/articles/view/193745/sd/6"
      }
    },
    {
      "id": "rs_08dd44399a824f1a00693c902c9de48195aeab04c126ad1e15",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_08dd44399a824f1a00693c9032622481959daeee99240cd2c3",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://www.jci.org/articles/view/193745/sd/6"
      }
    },
    {
      "id": "rs_08dd44399a824f1a00693c9034492081959f4d2550c6477dcd",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_08dd44399a824f1a00693c90358c6c8195befc519043bc95d0",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://www.jci.org/articles/view/193745/sd/6"
      }
    },
    {
      "id": "rs_08dd44399a824f1a00693c9036fbe88195b9c35d40da690c61",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_08dd44399a824f1a00693c903c3df481959909a7a0aadc843f",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "\"CDK12/13\" inhibitor \"NCT\" Phase 1"
      }
    },
    {
      "id": "rs_08dd44399a824f1a00693c903f8b388195bfe9cdcf7a98781f",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "msg_08dd44399a824f1a00693c90590af481958e99831977ab25b3",
      "type": "message",
      "status": "completed",
      "content": [
        {
          "type": "output_text",
          "annotations": [
            {
              "type": "url_citation",
              "end_index": 771,
              "start_index": 571,
              "title": "Carrick Therapeutics Announces First Patient Dosed in Phase",
              "url": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html"
            },
            {
              "type": "url_citation",
              "end_index": 1202,
              "start_index": 1121,
              "title": "\n\n    \n        Trial | NCT06600789\n    \n\n",
              "url": "https://cdek.pharmacy.purdue.edu/trial/NCT06600789/"
            },
            {
              "type": "url_citation",
              "end_index": 1676,
              "start_index": 1597,
              "title": "NCT06600789: An ongoing trial by Carrick Therapeutics Limited",
              "url": "https://fdaaa.trialstracker.net/trial/NCT06600789/"
            },
            {
              "type": "url_citation",
              "end_index": 2190,
              "start_index": 2060,
              "title": "Non-enzymatic SETD1A activity drives breast cancer cell proliferation via cyclin K | Breast Cancer Research",
              "url": "https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-025-02101-x"
            },
            {
              "type": "url_citation",
              "end_index": 2686,
              "start_index": 2595,
              "title": "CDK12/13 Inhibitor :: Carrick Therapeutics, Inc.",
              "url": "https://www.carricktherapeutics.com/pipeline/cdk1213-inhibitor"
            },
            {
              "type": "url_citation",
              "end_index": 3361,
              "start_index": 3198,
              "title": "Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor) - BioSpace",
              "url": "https://www.biospace.com/press-releases/carrick-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ct7439-cdk12-13-inhibitor"
            }
          ],
          "logprobs": [],
          "text": "- **Title:** Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor)  \n  - **URL:** `https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html`  \n  - **Direct quote snippets:**  \n    - “CT7439, a novel cyclin dependent kinase 12/13 (CDK12/13) inhibitor / Cyclin-K glue-degrader.”  \n    - “advanced solid tumors, including ovarian, breast and Ewing's Sarcoma.”  \n    - “under study ID: NCT06600789.” ([globenewswire.com](https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html))\n\n- **Title:** Trial | NCT06600789 (Clinical Drug Experience Knowledgebase / Purdue)  \n  - **URL:** `https://cdek.pharmacy.purdue.edu/trial/NCT06600789/`  \n  - **Direct quote snippets:**  \n    - “A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies”  \n    - “CT7439 Capsules (0.5 mg, 1mg, 3mg)”  \n    - “Trial | NCT06600789” ([cdek.pharmacy.purdue.edu](https://cdek.pharmacy.purdue.edu/trial/NCT06600789/))\n\n- **Title:** NCT06600789: An ongoing trial by Carrick Therapeutics Limited (FDAAA TrialsTracker)  \n  - **URL:** `https://fdaaa.trialstracker.net/trial/NCT06600789/`  \n  - **Direct quote snippets:**  \n    - “NCT06600789: An ongoing trial by Carrick Therapeutics Limited”  \n    - “Title  A Modular, Multi-Part, Multi-Arm, Phase 1/2 Study to Evaluate the Safety and Tolerability of CT7439 Alone” ([fdaaa.trialstracker.net](https://fdaaa.trialstracker.net/trial/NCT06600789/))\n\n- **Title:** Non-enzymatic SETD1A activity drives breast cancer cell proliferation via cyclin K (Breast Cancer Research)  \n  - **URL:** `https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-025-02101-x`  \n  - **Direct quote snippets:**  \n    - “CT7439, a dual inhibitor of CDK12/13 and a cyclin K glue degrader,”  \n    - “including breast cancer (NCT06600789).” ([breast-cancer-research.biomedcentral.com](https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-025-02101-x))\n\n- **Title:** CDK12/13 Inhibitor (Carrick Therapeutics pipeline page)  \n  - **URL:** `https://www.carricktherapeutics.com/pipeline/cdk1213-inhibitor`  \n  - **Direct quote snippets:**  \n    - “CT7439: CDK12/13 inhibitor/Cyclin-K Degrader”  \n    - “CT7439 is a CDK12/13/Cyclin-K degrader, which potently inhibits the cellular activity of CDK12/13.”  \n    - “including breast, ovarian and Ewing's Sarcoma.” ([carricktherapeutics.com](https://www.carricktherapeutics.com/pipeline/cdk1213-inhibitor))\n\n- **Title:** Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor) (BioSpace)  \n  - **URL:** `https://www.biospace.com/press-releases/carrick-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ct7439-cdk12-13-inhibitor`  \n  - **Direct quote snippets:**  \n    - “under study ID: NCT06600789.”  \n    - “CT7439 is an inhibitor of CDK12/13 as well as a 'glue degrader' of Cyclin-K”  \n    - “including ovarian, breast and Ewing's Sarcoma.” ([biospace.com](https://www.biospace.com/press-releases/carrick-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ct7439-cdk12-13-inhibitor))"
        }
      ],
      "role": "assistant"
    }
  ],
  "parallel_tool_calls": true,
  "previous_response_id": null,
  "prompt_cache_key": null,
  "prompt_cache_retention": null,
  "reasoning": {
    "effort": "medium",
    "summary": null
  },
  "safety_identifier": null,
  "service_tier": "default",
  "store": true,
  "temperature": 1.0,
  "text": {
    "format": {
      "type": "text"
    },
    "verbosity": "medium"
  },
  "tool_choice": "auto",
  "tools": [
    {
      "type": "web_search",
      "filters": null,
      "search_context_size": "medium",
      "user_location": {
        "type": "approximate",
        "city": null,
        "country": "US",
        "region": null,
        "timezone": null
      }
    }
  ],
  "top_logprobs": 0,
  "top_p": 0.98,
  "truncation": "disabled",
  "usage": {
    "input_tokens": 51762,
    "input_tokens_details": {
      "cached_tokens": 4352
    },
    "output_tokens": 5219,
    "output_tokens_details": {
      "reasoning_tokens": 4319
    },
    "total_tokens": 56981
  },
  "user": null,
  "metadata": {}
}